American pharmaceutical firm Pfizer Inc. said late-stage study results found that its experimental COVID-19 pill Paxlovid effectively reduces risks in adults, the firm reported in a statement.
- The latest study found that Paxlovid was 89% effective in reducing the hospitalization and death risks in adults at high risk of severe COVID-19 versus the placebo in non-hospitalized high-risk patients.
- Paxlovid was also found to reduce the risk of hospitalization or death for any cause by 88% for patients treated within five days of the symptom onset, higher than the 85% recorded in the interim analysis.
- Chairman and Chief Executive Officer Albert Bourla said the emergence of other variants of concern, such as Omicron, has exacerbated the need for accessible treatment options for individuals who contract the virus.
- The study looked into subjects at high risk of developing severe diseases and had to have at least one underlying health condition. Another study covered unvaccinated individuals and those at low risk of developing severe diseases.
The results come ahead of the review of the Food and Drug Administration which is expected to be finalized before the end of the year. PFE is up 0.47%.